"a:6:{s:5:\"LabNo\";s:6:\"DR1135\";s:7:\"Condons\";s:5:\"1-238\";s:7:\"SubType\";s:1:\"D\";s:19:\"PolymorphismResults\";a:3:{i:0;a:2:{s:14:\"Classification\";s:5:\"OTHER\";s:6:\"Result\";s:121:\"K14R,L19Q,M36I,R41K,L63Q,I64V,E65D,P4N,K20R,V35I,K49R,V60I,V118VIM,D121Y,K122E,D123E,I135T,G196E,I202V,Q207E,R211K,L228LH\";}i:1;a:2:{s:14:\"Classification\";s:4:\"NRTI\";s:6:\"Result\";s:27:\"M41L,E44D,M184V,L210W,T215Y\";}i:2;a:2:{s:14:\"Classification\";s:5:\"NNRTI\";s:6:\"Result\";s:5:\"K103N\";}}s:15:\"DrugScoreGroups\";a:3:{i:0;a:2:{s:4:\"Type\";s:5:\"NNRTI\";s:10:\"DrugScores\";a:4:{i:0;a:4:{s:8:\"DrugName\";s:9:\"efavirenz\";s:8:\"DrugCode\";s:3:\"EFV\";s:19:\"ResistanceLevelText\";s:21:\"High-Level Resistance\";s:12:\"DrugNameCode\";s:15:\"efavirenz (EFV)\";}i:1;a:4:{s:8:\"DrugName\";s:10:\"etravirine\";s:8:\"DrugCode\";s:3:\"ETR\";s:19:\"ResistanceLevelText\";s:11:\"Susceptible\";s:12:\"DrugNameCode\";s:16:\"etravirine (ETR)\";}i:2;a:4:{s:8:\"DrugName\";s:10:\"nevirapine\";s:8:\"DrugCode\";s:3:\"NVP\";s:19:\"ResistanceLevelText\";s:21:\"High-Level Resistance\";s:12:\"DrugNameCode\";s:16:\"nevirapine (NVP)\";}i:3;a:4:{s:8:\"DrugName\";s:11:\"rilpivirine\";s:8:\"DrugCode\";s:3:\"RPV\";s:19:\"ResistanceLevelText\";s:11:\"Susceptible\";s:12:\"DrugNameCode\";s:17:\"rilpivirine (RPV)\";}}}i:1;a:2:{s:4:\"Type\";s:4:\"NRTI\";s:10:\"DrugScores\";a:7:{i:0;a:4:{s:8:\"DrugName\";s:8:\"abacavir\";s:8:\"DrugCode\";s:3:\"ABC\";s:19:\"ResistanceLevelText\";s:21:\"High-Level Resistance\";s:12:\"DrugNameCode\";s:14:\"abacavir (ABC)\";}i:1;a:4:{s:8:\"DrugName\";s:10:\"zidovudine\";s:8:\"DrugCode\";s:3:\"AZT\";s:19:\"ResistanceLevelText\";s:21:\"High-Level Resistance\";s:12:\"DrugNameCode\";s:16:\"zidovudine (AZT)\";}i:2;a:4:{s:8:\"DrugName\";s:9:\"stavudine\";s:8:\"DrugCode\";s:3:\"D4T\";s:19:\"ResistanceLevelText\";s:21:\"High-Level Resistance\";s:12:\"DrugNameCode\";s:15:\"stavudine (D4T)\";}i:3;a:4:{s:8:\"DrugName\";s:10:\"didanosine\";s:8:\"DrugCode\";s:3:\"DDI\";s:19:\"ResistanceLevelText\";s:21:\"High-Level Resistance\";s:12:\"DrugNameCode\";s:16:\"didanosine (DDI)\";}i:4;a:4:{s:8:\"DrugName\";s:13:\"emtricitabine\";s:8:\"DrugCode\";s:3:\"FTC\";s:19:\"ResistanceLevelText\";s:21:\"High-Level Resistance\";s:12:\"DrugNameCode\";s:19:\"emtricitabine (FTC)\";}i:5;a:4:{s:8:\"DrugName\";s:10:\"lamivudine\";s:8:\"DrugCode\";s:3:\"3TC\";s:19:\"ResistanceLevelText\";s:21:\"High-Level Resistance\";s:12:\"DrugNameCode\";s:16:\"lamivudine (3TC)\";}i:6;a:4:{s:8:\"DrugName\";s:9:\"tenofovir\";s:8:\"DrugCode\";s:3:\"TDF\";s:19:\"ResistanceLevelText\";s:23:\"Intermediate Resistance\";s:12:\"DrugNameCode\";s:15:\"tenofovir (TDF)\";}}}i:2;a:2:{s:4:\"Type\";s:2:\"PI\";s:10:\"DrugScores\";a:8:{i:0;a:4:{s:8:\"DrugName\";s:12:\"atazanavir\/r\";s:8:\"DrugCode\";s:5:\"ATV\/r\";s:19:\"ResistanceLevelText\";s:11:\"Susceptible\";s:12:\"DrugNameCode\";s:20:\"atazanavir\/r (ATV\/r)\";}i:1;a:4:{s:8:\"DrugName\";s:11:\"darunavir\/r\";s:8:\"DrugCode\";s:5:\"DRV\/r\";s:19:\"ResistanceLevelText\";s:11:\"Susceptible\";s:12:\"DrugNameCode\";s:19:\"darunavir\/r (DRV\/r)\";}i:2;a:4:{s:8:\"DrugName\";s:15:\"fosamprenavir\/r\";s:8:\"DrugCode\";s:5:\"FPV\/r\";s:19:\"ResistanceLevelText\";s:11:\"Susceptible\";s:12:\"DrugNameCode\";s:23:\"fosamprenavir\/r (FPV\/r)\";}i:3;a:4:{s:8:\"DrugName\";s:11:\"indinavir\/r\";s:8:\"DrugCode\";s:5:\"IDV\/r\";s:19:\"ResistanceLevelText\";s:11:\"Susceptible\";s:12:\"DrugNameCode\";s:19:\"indinavir\/r (IDV\/r)\";}i:4;a:4:{s:8:\"DrugName\";s:11:\"lopinavir\/r\";s:8:\"DrugCode\";s:5:\"LPV\/r\";s:19:\"ResistanceLevelText\";s:11:\"Susceptible\";s:12:\"DrugNameCode\";s:19:\"lopinavir\/r (LPV\/r)\";}i:5;a:4:{s:8:\"DrugName\";s:10:\"nelfinavir\";s:8:\"DrugCode\";s:3:\"NFV\";s:19:\"ResistanceLevelText\";s:11:\"Susceptible\";s:12:\"DrugNameCode\";s:16:\"nelfinavir (NFV)\";}i:6;a:4:{s:8:\"DrugName\";s:12:\"saquinavir\/r\";s:8:\"DrugCode\";s:5:\"SQV\/r\";s:19:\"ResistanceLevelText\";s:11:\"Susceptible\";s:12:\"DrugNameCode\";s:20:\"saquinavir\/r (SQV\/r)\";}i:7;a:4:{s:8:\"DrugName\";s:12:\"tipranavir\/r\";s:8:\"DrugCode\";s:5:\"TPV\/r\";s:19:\"ResistanceLevelText\";s:11:\"Susceptible\";s:12:\"DrugNameCode\";s:20:\"tipranavir\/r (TPV\/r)\";}}}}s:14:\"ResultComments\";a:3:{i:0;a:2:{s:5:\"Group\";s:4:\"NRTI\";s:8:\"Comments\";a:5:{i:0;s:319:\"M184V\/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V\/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.\";i:1;s:217:\"L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF.\";i:2;s:159:\"T215Y is a TAM that causes intermediate\/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.\";i:3;s:195:\"M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate \/ high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.\";i:4;s:144:\"E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs.\";}}i:1;a:2:{s:5:\"Group\";s:5:\"NNRTI\";s:8:\"Comments\";a:1:{i:0;s:85:\"K103N is a non-polymorphic mutation that causes high-level resistance to NVP and EFV.\";}}i:2;a:2:{s:5:\"Group\";s:5:\"Other\";s:8:\"Comments\";a:1:{i:0;s:110:\"V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs.\";}}}}"